MA55781A - Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 - Google Patents

Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2

Info

Publication number
MA55781A
MA55781A MA055781A MA55781A MA55781A MA 55781 A MA55781 A MA 55781A MA 055781 A MA055781 A MA 055781A MA 55781 A MA55781 A MA 55781A MA 55781 A MA55781 A MA 55781A
Authority
MA
Morocco
Prior art keywords
aprmilast
combination therapies
therapies including
tyk2 inhibitors
tyk2
Prior art date
Application number
MA055781A
Other languages
English (en)
Inventor
Mary Adams
Lisa Beebe
Gilles Buchwalter
Tiffany Carr
Robert Plenge
Peter Henry Schafer
Te-Chen Tzeng
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Priority to MA055781A priority Critical patent/MA55781A/fr
Publication of MA55781A publication Critical patent/MA55781A/fr

Links

MA055781A 2019-04-30 2019-04-30 Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 MA55781A (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MA055781A MA55781A (fr) 2019-04-30 2019-04-30 Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MA055781A MA55781A (fr) 2019-04-30 2019-04-30 Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2

Publications (1)

Publication Number Publication Date
MA55781A true MA55781A (fr) 2022-03-09

Family

ID=82258120

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055781A MA55781A (fr) 2019-04-30 2019-04-30 Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2

Country Status (1)

Country Link
MA (1) MA55781A (fr)

Similar Documents

Publication Publication Date Title
MA55799A (fr) Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
IL282487A (en) TYK2 inhibitors and their use
GB201909190D0 (en) Therapeutic agents
MA44890A (fr) Compositions comprenant des souches bactériennes
GB201909194D0 (en) Therapeutic agents
GB201909191D0 (en) Therapeutic agents
MA46716A (fr) Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
IL282090A (en) tyk2 inhibitors and uses thereof
IL286248A (en) tyk2 inhibitors and their use
IL284799A (en) TYK2 inhibitors and uses thereof
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
IL276609A (en) Combined treatment with epilimod and glutamatergic factors
IL279810A (en) Heteroaryl-converted sulfonamide compounds and their use as medicinal agents
MA47074A (fr) Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires
MA52165A (fr) Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée
GB201902277D0 (en) Therapeutic agents
ZA202100092B (en) Modified cas9 protein and use thereof
MA55816A (fr) Combinaisons thérapeutiques comprenant des immunoconjugués anti-cd123
GB201918541D0 (en) Therapeutic compounds and their use
GB201906804D0 (en) Therapeutic agents
PT3937949T (pt) Fitoecdisonas e seus derivados para utilização no tratamento da alteração da função respiratória
MA55781A (fr) Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
IL289531A (en) cd38 binding agents and uses thereof
IL288828A (en) Binding factors - cd38 and their use
GB201905520D0 (en) Compounds and their therapeutic use